

Ha

Kn

Li

SF

SS

SH

Wa

Wi

WL



PAN MERSEY AREA PRESCRIBING COMMITTEE  
PRESCRIBING POLICY STATEMENT  
REF: PS206 FINAL  
APC BOARD DATE: 31 JAN 2018



Pan Mersey  
Area Prescribing Committee

## NALTREXONE-BUPROPION 8 mg/90 mg prolonged-release tablets (Mysimba®▼)

**B  
L  
A  
C  
K**

**The Pan Mersey Area Prescribing Committee does not recommend the prescribing of NALTREXONE-BUPROPION 8 mg/90 mg prolonged-release tablets (Mysimba®▼) for managing overweight and obesity in accordance with NICE TA494.**

Naltrexone-bupropion (Mysimba®)<sup>1</sup> is licensed as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of:

- ≥ 30 kg/m<sup>2</sup> (obese), or
- ≥ 27 kg/m<sup>2</sup> to < 30 kg/m<sup>2</sup> (overweight) in the presence of one or more weight-related co-morbidities (e.g. type 2 diabetes, dyslipidaemia, or controlled hypertension).

NICE technology appraisal TA494<sup>2</sup> [12 December 2017] does **not** recommend naltrexone-bupropion 8 mg/90 mg prolonged-release tablets (Mysimba®▼) for managing overweight and obesity because:

- > The estimate of cost effectiveness for naltrexone–bupropion with lifestyle measures, compared with lifestyle measures alone, is highly uncertain because of uncertainties in the modelling assumptions.
- > Large numbers of people could be eligible for treatment which could potentially be long-term, leading to high overall costs for naltrexone–bupropion. Therefore, in these circumstances more certainty is needed that naltrexone–bupropion will provide value for the NHS.

Treatment of obesity and overweight patients should follow the guidance from NICE CG189 [November 2014]: [Obesity: identification, assessment and management](#).

NICE has also produced guidance on [obesity prevention](#), [maintaining a healthy weight](#), and [lifestyle weight management services](#).

### References

1. Consilient Health Ltd. Summary of Product Characteristics: Mysimba 8mg/90mg prolonged-release tablets. 01 November 2017. Accessed 28 December 2017 at: <http://www.medicines.org.uk/emc/medicine/33484>
2. NICE TA494 Naltrexone–bupropion for managing overweight and obesity. 12 December 2017. Accessed 28 December 2017 at <https://www.nice.org.uk/guidance/ta494>

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.